A recent publication in Genes & Diseases has delivered a compelling synthesis of the latest insights into the cellular ...

Cogent Biosciences, Inc.’s COGT share price has surged by 7.51%, which has investors questioning if this is right time to sell.

A recent publication in Genes & Diseases has delivered a compelling synthesis of the latest insights into the cellular ...

Treatment of chronic myeloid leukemia (CML) has changed drastically with the emergence of the Abl tyrosine kinase inhibitor (TKI), imatinib mesylate. However, primary and secondary resistance have ...

The oral FGFR1-3 selective tyrosine kinase inhibitor infigratinib was found ... but may have found new life in achondroplasia. The FGFR inhibitor had been granted accelerated approval in 2022 ...

Nuvalent Inc. has identified proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.

a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI ...

The molecular basis of phospho-tyrosyl-regulation of Src-family and Syk-family protein tyrosine kinases in signaling pathways is a current focus of the lab. The conformational activation of Src kinase ...

1). The phosphorylation of the biotin-tagged generic peptide is initiated by the addition of ATP in the presence of the tyrosine kinase (step 1) and stopped by the addition of a mix containing the ...

Tyrosine kinase domains are represented by TK. Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of ...